These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 7334406

  • 1. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A, Giovannini P, Parati E, Novelli A, Caraceni T, Müller EE.
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [Abstract] [Full Text] [Related]

  • 2. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
    Martinez-Campos A, Giovannini P, Novelli A, Cocchi D, Caraceni T, Müller EE.
    Acta Endocrinol (Copenh); 1982 Mar; 99(3):344-51. PubMed ID: 6803485
    [Abstract] [Full Text] [Related]

  • 3. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK, Rinne JO.
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
    Chouza C, Caamaño JL, de Medina O, Aljanati R, Scaramelli A, Romero S.
    J Neural Transm Suppl; 1988 Nov; 27():61-70. PubMed ID: 3042913
    [Abstract] [Full Text] [Related]

  • 10. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD.
    Eur Neurol; 1987 Nov; 27 Suppl 1():54-8. PubMed ID: 3322837
    [Abstract] [Full Text] [Related]

  • 11. Madopar versus sinemet. A clinical study on their effectiveness.
    Korten JJ, Keyser A, Joosten EM, Gabreëls FJ.
    Eur Neurol; 1975 Nov; 13(2):65-71. PubMed ID: 1095374
    [Abstract] [Full Text] [Related]

  • 12. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
    Grahnén A, Eckernäs SA, Collin C, Ling-Andersson A, Tiger G, Nilsson M.
    Eur Neurol; 1992 Nov; 32(6):343-8. PubMed ID: 1490503
    [Abstract] [Full Text] [Related]

  • 13. Enantiomeric composition of urinary salsolinol in parkinsonian patients after Madopar.
    Dostert P, Strolin Benedetti M, Dordain G, Vernay D.
    J Neural Transm Park Dis Dement Sect; 1989 Nov; 1(4):269-78. PubMed ID: 2597313
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
    Jansen EN, Meerwaldt JD, Heersema T, van Manen J, Speelman JD.
    Eur Neurol; 1987 Nov; 27 Suppl 1():88-92. PubMed ID: 3322841
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
    Caraceni TA, Celano I, Parati E, Girotti F.
    J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1142-6. PubMed ID: 591982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.